Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

717

10.17650/1726-9776-2017-13-3-18-26

LECTURE

ЛЕКЦИЯ

Nivolumab as the new standard of metastatic kidney cancer treatment

Ниволумаб – новый стандарт в лечении метастатического рака почки

Matveev

V. B.

Матвеев

В. Б.

Russian Federation

24 Kashirskoe Shosse, Moscow 115478, Russia

член-корреспондент РАН, профессор, заведующий отделением урологическим

Россия, 115478 Москва, Каширское шоссе, 24

vsevolodmatveev@mail.ru

Research Institute of Clinical Oncology, N. N. Blokhin National Medical Research Oncology Center, Ministry of Health of RussiaНИИ клинической онкологии ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России

30092017

133

18261909201721092017

https://oncourology.abvpress.ru/oncur/article/view/717

The last decade was marked by the rapid development of kidney cancer drug treatment and advent of targeted drugs aimed at inhibition of angiogenesis which plays a crucial role in tumor growth. Despite certain success, targeted antiangiogenetic therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors (mTOR), and monoclonal antibodies against vascular endothelial growth factor (VEGF) in most cases do not achieve long-term remission, are highly toxic, and never lead to full cure for the patients. Development of modern immunological approaches to application of inhibitors of the crucial immune response regulators opens up new possibilities in treatment of disseminated kidney cancer. In this review, results of the studies of nivolumab (PD-1 inhibitor), first checkpoint inhibitor registered for treatment of metastatic kidney cancer are presented.

Последнее десятилетие ознаменовалось бурным развитием лекарственного лечения рака почки и появлением таргетных препаратов, направленных на блокаду ангиогенеза, имеющего ключевое значение в опухолевом росте. Несмотря на определенные успехи, таргетная антиангиогенная терапия с использованием ингибиторов тирозинкиназ, ингибиторов мишени рапамицина млекопитающих (mTOR) и моноклональных антител к фактору роста эндотелия сосудов (VEGF) в большинстве случаев не обеспечивает длительной ремиссии, обладает высокой токсичностью и никогда не приводит к полному излечению пациентов. Появление современных иммунологических подходов с включением ингибиторов ключевых регуляторов иммунного ответа открывает новые возможности в терапии диссеминированного рака почки. В данном обзоре приведены результаты исследований препарата ниволумаб (ингибитора PD-1), первого чекпоинт-ингибитора, зарегистрированного для лечения метастатического рака почки.

kidney cancernivolumabimmunotherapy

рак почкиниволумабиммунотерапия

1. Состояние онкологической помощи населению России в 2015 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 236 с. [State of oncological care in Russia in 2015. Eds.: A. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 236 p. (In Russ.)].

Состояние онкологической помощи населению России в 2015 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 236 с. [State of oncological care in Russia in 2015. Eds.: A. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 236 p. (In Russ.)].

2. Surveillance, epidemiology, and end results program. SEER stat fact sheets: kidney and renal pelvis cancer. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/ statfacts/html/kidrp.html.

Surveillance, epidemiology, and end results program. SEER stat fact sheets: kidney and renal pelvis cancer. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/ statfacts/html/kidrp.html.

3. Dabestani S., Thorstenson A., Lindblad P. et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 2016;34(8):1081–6. DOI: 10.1007/s00345-016-1773-y. PMID: 26847337.

Dabestani S., Thorstenson A., Lindblad P. et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 2016;34(8):1081–6. DOI: 10.1007/s00345-016-1773-y. PMID: 26847337.

4. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:49–56. DOI: 10.1093/annonc/mdu259. PMID: 25210086.

Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:49–56. DOI: 10.1093/annonc/mdu259. PMID: 25210086.

5. Motzer R., Hutson T., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal- cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI: 10.1056/NEJMoa065044. PMID: 17215529.

Motzer R., Hutson T., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal- cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI: 10.1056/NEJMoa065044. PMID: 17215529.

6. Rini B., Halabi S., Rosenberg J. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI: 10.1200/JCO.2009.26.5561.

Rini B., Halabi S., Rosenberg J. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI: 10.1200/JCO.2009.26.5561.

PMID: 20368558.

7. Sternberg C. N., Davis I. D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI: 10.1200/JCO.2009.23.9764. PMID: 20100962.

Sternberg C. N., Davis I. D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI: 10.1200/JCO.2009.23.9764. PMID: 20100962.

8. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5(12):1365–9. DOI: 10.1038/70932. PMID: 10581077.

Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5(12):1365–9. DOI: 10.1038/70932. PMID: 10581077.

10.

9. Hodi F. S., O’Day S. J. McDermott D. F. et al. Improved survival with ipilimumab in patients with metastatic elanoma. N Engl J Med 2010;363(8):711–23. DOI: 10.1056/NEJMoa1003466. PMID: 20525992.

Hodi F. S., O’Day S. J. McDermott D. F. et al. Improved survival with ipilimumab in patients with metastatic elanoma. N Engl J Med 2010;363(8):711–23. DOI: 10.1056/NEJMoa1003466. PMID: 20525992.

11.

10. Thompson R. H., Kuntz S. M., Leibovich B. C. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-termfollow-up. Cancer Res 2006;66(7):3381–5. DOI: 10.1158/0008–5472.CAN-05–4303. PMID: 16585157.

Thompson R. H., Kuntz S. M., Leibovich B. C. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-termfollow-up. Cancer Res 2006;66(7):3381–5. DOI: 10.1158/0008–5472.CAN-05–4303. PMID: 16585157.

12.

11. Brahmer J. R., Drake C. G., Wollner I. et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167–75. DOI: 10.1200/JCO.2009.26.7609. PMID: 20516446.

Brahmer J. R., Drake C. G., Wollner I. et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167–75. DOI: 10.1200/JCO.2009.26.7609. PMID: 20516446.

13.

12. Topalian S. L., Sznol M., McDermott D.F. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32(10):1020–30. DOI: 10.1200/JCO.2013.53.0105. PMID: 24590637.

Topalian S. L., Sznol M., McDermott D.F. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32(10):1020–30. DOI: 10.1200/JCO.2013.53.0105. PMID: 24590637.

14.

13. OPDIVO Summary of Product Characteristics. 1506UK1600152-05 Date of preparation: May 2016.

OPDIVO Summary of Product Characteristics. 1506UK1600152-05 Date of preparation: May 2016.

15.

14. Motzer R. J., Rini B. I., McDermott D.F. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;33(13):1430–7. DOI: 10.1200/JCO.2014.59.0703. PMID: 25452452.

Motzer R. J., Rini B. I., McDermott D.F. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;33(13):1430–7. DOI: 10.1200/JCO.2014.59.0703. PMID: 25452452.

16.

15. Motzer R. J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI: 10.1056/NEJMoa1510665. PMID: 26406148.

Motzer R. J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI: 10.1056/NEJMoa1510665. PMID: 26406148.

17.

16. Adapted from poster presented by E. R. Plimack et al. 15th International Kidney Cancer Symposium. November 4–5, 2016. Miami, FL, USA.

Adapted from poster presented by E. R. Plimack et al. 15th International Kidney Cancer Symposium. November 4–5, 2016. Miami, FL, USA.

18.

17. Escudier B., Sharma P., McDermott D.F. et al. CheckMate 025 Randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol 2017. DOI: 10.1016/j.eururo.2017.02.010. PMID: 28262413.

Escudier B., Sharma P., McDermott D.F. et al. CheckMate 025 Randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol 2017. DOI: 10.1016/j.eururo.2017.02.010. PMID: 28262413.

19.

18. Presented by D. McDermott at 2016 ASCO Annual Meeting.

Presented by D. McDermott at 2016 ASCO Annual Meeting.

20.

19. Thompson R. H., Kuntz S. M., Leibovich B. C. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66(7):3381–85. DOI: 10.1158/0008–5472.CAN-05–4303. PMID: 16585157.

Thompson R. H., Kuntz S. M., Leibovich B. C. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66(7):3381–85. DOI: 10.1158/0008–5472.CAN-05–4303. PMID: 16585157.

21.

20. Xu F., Xu L., Wang Q. et al. Clinicopathological and prognostic value of programmed death ligand-1 (PD–L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med 2015;8(9):14595–603. PMID: 26628942.

Xu F., Xu L., Wang Q. et al. Clinicopathological and prognostic value of programmed death ligand-1 (PD–L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med 2015;8(9):14595–603. PMID: 26628942.

22.

21. Powles T., Staehler M., Ljungberg B. et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 2016;69(1):4–6. DOI: 10.1016/j.eururo.2015.10.017. PMID: 26508312.

Powles T., Staehler M., Ljungberg B. et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 2016;69(1):4–6. DOI: 10.1016/j.eururo.2015.10.017. PMID: 26508312.

23.

22. Heine A., Held S. A., Bringmann A. et al. Immunomodulatory effects of antiangiogenic drugs. Leukemia 2011;25(6):899–905. DOI: 10.1038/leu.2011.24. PMID: 21350557.

Heine A., Held S. A., Bringmann A. et al. Immunomodulatory effects of antiangiogenic drugs. Leukemia 2011;25(6):899–905. DOI: 10.1038/leu.2011.24. PMID: 21350557.

24.

23. Choueiri T. K., Figueroa D. J., Fay A. P. et al. Correlation of PD–L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015;21(5):1071–7. DOI: 10.1158/1078–0432.CCR-14–1993. PMID: 25538263.

Choueiri T. K., Figueroa D. J., Fay A. P. et al. Correlation of PD–L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015;21(5):1071–7. DOI: 10.1158/1078–0432.CCR-14–1993. PMID: 25538263.

25.

24. Hammers H. J., Plimack E. R., Infante J. R. et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017. DOI: 10.1200/JCO.2016.72.1985. PMID: 28678668.

Hammers H. J., Plimack E. R., Infante J. R. et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017. DOI: 10.1200/JCO.2016.72.1985. PMID: 28678668.

26.

25. Bristol-Myers Squibb. Clinicaltrials. gov. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214). Available at: https://clinicaltrials. gov/ct2/show/NCT02231749 (Accessed August 19, 2017).

Bristol-Myers Squibb. Clinicaltrials. gov. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214). Available at: https://clinicaltrials. gov/ct2/show/NCT02231749 (Accessed August 19, 2017).

27.

26. Escudier B. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naive advanced or metastatic renal cell carcinoma, including IMDC risk and PD–L1 expression subgroups. Oral presentation at the 42nd European Society of Medical Oncology (ESMO) Annual Meeting. September 8–12, 2017. Madrid, Spain.

Escudier B. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naive advanced or metastatic renal cell carcinoma, including IMDC risk and PD–L1 expression subgroups. Oral presentation at the 42nd European Society of Medical Oncology (ESMO) Annual Meeting. September 8–12, 2017. Madrid, Spain.

28.

27. Eichelberg C., Vervenne W., De Santis M. et al. SWITCH: a randomised, sequential, open- label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib- sorafenib in the treatment of metastatic renal cell cancer. Eur Urol 2015;68(5):837–47. DOI: 10.1016/j.eururo.2015.04.017. PMID: 25952317.

Eichelberg C., Vervenne W., De Santis M. et al. SWITCH: a randomised, sequential, open- label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib- sorafenib in the treatment of metastatic renal cell cancer. Eur Urol 2015;68(5):837–47. DOI: 10.1016/j.eururo.2015.04.017. PMID: 25952317.

29.

28. Rexer H., AUO. First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 – AN 33/11). Urology 2014;53(5):735–8. DOI: 10.1007/s00120-014-3459-7. PMID: 24727992.

Rexer H., AUO. First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 – AN 33/11). Urology 2014;53(5):735–8. DOI: 10.1007/s00120-014-3459-7. PMID: 24727992.

30.

29. Choueiri T. K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1814–23. DOI: 10.1056/NEJMoa1510016. PMID: 26406150.

Choueiri T. K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1814–23. DOI: 10.1056/NEJMoa1510016. PMID: 26406150.

31.

30. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines for Kidney Cancer®) Renal Cell Carcinoma V.2, 2017.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines for Kidney Cancer®) Renal Cell Carcinoma V.2, 2017.

32.

31. Escudier B., Porta C., Shmidinger M. et al. Renal cell carcinoma ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl 5): 58–68. DOI: 10.1093/annonc/mdw328. PMID: 27664262.

Escudier B., Porta C., Shmidinger M. et al. Renal cell carcinoma ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl 5): 58–68. DOI: 10.1093/annonc/mdw328. PMID: 27664262.

33.

32. George S., Motzer R. J., Hammers H. J. et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2016;2(9):1179–86. DOI: 10.1001/jamaoncol.2016.0775. PMID: 27243803.

George S., Motzer R. J., Hammers H. J. et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2016;2(9):1179–86. DOI: 10.1001/jamaoncol.2016.0775. PMID: 27243803.

34.

33. Escudier B., Motzer R., Sharma P. et al. Treatment beyond progression in patients with advanced renal cell carcinoma in the phase III CheckMate 025 study of nivolumab versus everolimus. ASCO Meeting 2016. Abst 34: 4509.

Escudier B., Motzer R., Sharma P. et al. Treatment beyond progression in patients with advanced renal cell carcinoma in the phase III CheckMate 025 study of nivolumab versus everolimus. ASCO Meeting 2016. Abst 34: 4509.

35.

34. Choueiri T. K., Fay A. P., Gray K. P. et al. PD–L1 expression in non clear-cell renal cell carcinoma. Ann Oncol 2014;25(11): 2178–84. DOI: 10.1093/annonc/mdu445. PMID: 25193987.

Choueiri T. K., Fay A. P., Gray K. P. et al. PD–L1 expression in non clear-cell renal cell carcinoma. Ann Oncol 2014;25(11): 2178–84. DOI: 10.1093/annonc/mdu445. PMID: 25193987.

36.

35. Rimar K. J., Meeks J. J., Kuzel T. M. Antiprogrammed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma. Clin Genitourin Cancer 2016;14(4):431–4. DOI: 10.1016/j.clgc.2016.02.013. PMID: 27021586.

Rimar K. J., Meeks J. J., Kuzel T. M. Antiprogrammed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma. Clin Genitourin Cancer 2016;14(4):431–4. DOI: 10.1016/j.clgc.2016.02.013. PMID: 27021586.

37.

36. Rouvinov K., Osyntsov L., Shaco-Levy R. et al. Rapid response to Nivolumab in a patient with sarcomatoid transformation of chromophobe renal cell carcinoma. Clin Genitourin Cancer 2017; S1558–7673(17):30165–9. DOI: 10.1016/j.clgc.2017.05.028. PMID: 28673798.

Rouvinov K., Osyntsov L., Shaco-Levy R. et al. Rapid response to Nivolumab in a patient with sarcomatoid transformation of chromophobe renal cell carcinoma. Clin Genitourin Cancer 2017; S1558–7673(17):30165–9. DOI: 10.1016/j.clgc.2017.05.028. PMID: 28673798.

38.

37. Adrianzen Herrera D. A., Fleisig S. B., Gartrell B. A. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: on-label but without evidence. Invest New Drugs 2017. DOI: 10.1007/s10637-017-0469-5. PMID: 28466375.

Adrianzen Herrera D. A., Fleisig S. B., Gartrell B. A. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: on-label but without evidence. Invest New Drugs 2017. DOI: 10.1007/s10637-017-0469-5. PMID: 28466375.